Literature DB >> 11092782

Correlation between type II nitric oxide synthase and p53 expression in oral squamous cell carcinoma.

P A Brennan1, M Palacios-Callender, T Umar, D Hughes, A V Spedding, G A Zaki, J D Langdon.   

Abstract

Prolonged nitric oxide (NO) production by the enzyme type II nitric oxide synthase (NOS2) has been implicated in angiogenesis and metastasis of human cancers. In animal models, wild-type p53 (but not mutant) protein results in down-regulation of NOS2 expression, which reduces both tumour growth and dissemination. In the current study, we aimed to find out whether a correlation was present in oral squamous cell carcinoma. Fifty-six cases of squamous cell carcinoma were assessed immunohistochemically using antibodies to NOS2 and p53 (clone DO-7). We also confirmed NOS2 protein expression in selected cases using immunoblotting. The results were correlated with clinicopathological findings. Statistical analysis showed a significant relationship between p53 and NOS2 expression (P= 0.001). No relationship was found between size of tumour or histological degree of differentiation, and NOS2 expression in the primary tumour. Copyright 2000 The British Association of Oral and Maxillofacial Surgeons.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11092782     DOI: 10.1054/bjom.2000.0540

Source DB:  PubMed          Journal:  Br J Oral Maxillofac Surg        ISSN: 0266-4356            Impact factor:   1.651


  2 in total

1.  The mRNA expression of inducible nitric oxide synthase in DMBA-induced hamster buccal-pouch carcinomas: an in situ RT-PCR study.

Authors:  Chen Yuk-Kwan; Hsue Shui-Sang; Lin Li-Min
Journal:  Int J Exp Pathol       Date:  2002-06       Impact factor: 1.925

2.  Red Mold Rice Mitigates Oral Carcinogenesis in 7,12-Dimethyl-1,2-Benz[a]anthracene-Induced Oral Carcinogenesis in Hamster.

Authors:  Ruei-Lan Tsai; Bing-Ying Ho; Tzu-Ming Pan
Journal:  Evid Based Complement Alternat Med       Date:  2011-05-04       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.